Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Dropropizine and its isomer levodropropizine are peripherally acting non-opioid suppressants of non-productive cough. They are administered orally three or four times a day.
At the date of last update we found no published data on its excretion in breast milk.
Its pharmacokinetic data (low molecular weight, low binding to plasma proteins) make it likely to pass into milk in an amount that could be significant.
Its possible side effects are neither frequent nor serious: fatigue, drowsiness, nausea, diarrhea... (XFarma 2024, AEMPS 2014)
Product with very few bibliographic references and/or very old, marketed in few countries.
Until more published data on this drug in relation to breastfeeding are known, safer alternatives may be preferable, especially during the neonatal period and in case of prematurity.
If used in breastfeeding it is advisable to use the lowest effective dose and for the shortest possible time. Monitor drowsiness and adequate feeding of the infant.